W. Todd Myers, C.P.A., is a veteran financial executive with significant management experience in both public and private drug discovery/development companies. Mr. Myers is currently a member of the Board of Advisors of BioLaurus, Inc., a contract research organization specializing in cutting edge molecular imaging and high content analysis services for the biotechnology and pharmaceutical industry. He also provides coaching and guidance to start-up life science companies as an Entrepreneur-in-Residence at CONNECT, a non-profit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. Most recently, Mr. Myers was the Chief Financial Officer of SGX Pharmaceuticals, Inc., a publicly-traded biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics, and was instrumental in the sale of SGX to Eli Lilly & Company at a premium of 119% to its then-current trading price. Prior to SGX, as the Director of Finance at CombiChem, Inc, a publicly-traded computational drug discovery company, Mr. Myers managed all financial operations and was the senior financial representative on the team responsible for the sale of the company to DuPont Pharmaceuticals. He was also the Chief Financial Officer of FeRx Incorporated, a privately-held, clinical stage company dedicated to the development of oncology products, and has held positions with Premier Inc. and with Ernst & Young LLP. Mr. Myers received his B.S. in Accounting from the University of Illinois.
With over 37 years of pharmaceutical industry experience, Tim is a founding officer and the current President/CEO of RMC Pharmaceutical Solutions Incorporated (RMC). This experience extends across several pharma organizations ranging from large global operations (American Home Products/Wyeth-Ayerst) and mid-size development programs (Amylin Pharmaceuticals), to early-stage/startup companies (FeRx Incorporated and RMC). This uniquely diverse background, includes direct experience spanning the entire GxP spectrum (i.e., GMP, GLP, GCP, GDP and GVP) of activities that support the pre-clinical/clinical research, CMC/product development and commercialization of regulated drug and device products on a global basis. This background is not only an asset in the executive team's management of RMC's corporate development and sustained growth, but it has also been vital in allowing Tim to serve RMC clients as a Principal Consultant with contemporary, cross-functional global GxP expertise.
Scott is a founding member of RMC Pharmaceutical Solutions, and currently serves as its technical leader. Scott brings 28 years experience in the pharmaceutical industry, and an additional seven years of academic and government sponsored research and development in bioprocessing, to the RMC Pharmaceutical Solutions team. Since joining RMC Pharmaceutical Solutions in May 2004, Scott has been involved in a wide variety of projects for small and large biotech/pharmaceutical companies. He has overseen and/or performed assay, equipment, sterilization, cleaning and process validation, formulation development, due diligence for a multimillion dollar investment, construction of a new GMP facility for tissue processing, and tech transfer for a major late stage biotechnology product. Scott received his PhD in chemical engineering from Purdue University in 1989. In his last position, Scott served as the Vice President of Operations at FeRx Incorporated, overseeing manufacturing, process and product development, analytical development, formulation, facility design, construction and operation, and intellectual property. He is an adjunct professor of chemical engineering at the University of Colorado, a guest researcher at the National Institute of Standards and Technology, and co-author of a leading text book on bioseparations. Scott has also worked at Amylin Pharmaceuticals Incorporated, Synergen Incorporated, and the National Institute of Standards and Technology.